Nothing Special   »   [go: up one dir, main page]

WO2000042068A3 - Nouveaux peptides associes au vih - Google Patents

Nouveaux peptides associes au vih Download PDF

Info

Publication number
WO2000042068A3
WO2000042068A3 PCT/US2000/000372 US0000372W WO0042068A3 WO 2000042068 A3 WO2000042068 A3 WO 2000042068A3 US 0000372 W US0000372 W US 0000372W WO 0042068 A3 WO0042068 A3 WO 0042068A3
Authority
WO
WIPO (PCT)
Prior art keywords
related peptides
hiv
hiv related
antibodies
epitopes
Prior art date
Application number
PCT/US2000/000372
Other languages
English (en)
Other versions
WO2000042068A9 (fr
WO2000042068A2 (fr
Inventor
Giuseppe Scala
Xueni Chen
Oren J Cohen
Anthony Fauci
Original Assignee
Us Gov Health & Human Serv
Giuseppe Scala
Xueni Chen
Oren J Cohen
Anthony Fauci
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Giuseppe Scala, Xueni Chen, Oren J Cohen, Anthony Fauci filed Critical Us Gov Health & Human Serv
Priority to AU26031/00A priority Critical patent/AU2603100A/en
Priority to EP00904245A priority patent/EP1159297A2/fr
Priority to US09/869,003 priority patent/US6911527B1/en
Publication of WO2000042068A2 publication Critical patent/WO2000042068A2/fr
Publication of WO2000042068A3 publication Critical patent/WO2000042068A3/fr
Publication of WO2000042068A9 publication Critical patent/WO2000042068A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention porte sur la découverte de nouveaux épitopes et anticorps spécifiques associés à la survie à long terme des infections par le VIH-1. Lesdits épitopes et anticorps peuvent servir à la préparation de vaccins prévenant les infections par le VIH-1, et à limiter la progression du sida.
PCT/US2000/000372 1999-01-11 2000-01-07 Nouveaux peptides associes au vih WO2000042068A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU26031/00A AU2603100A (en) 1999-01-11 2000-01-07 Novel hiv related peptides
EP00904245A EP1159297A2 (fr) 1999-01-11 2000-01-07 Nouveaux peptides associes au vih
US09/869,003 US6911527B1 (en) 1999-01-11 2000-01-07 HIV related peptides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11543099P 1999-01-11 1999-01-11
US60/115,430 1999-01-11
US13276099P 1999-05-06 1999-05-06
US60/132,760 1999-05-06

Publications (3)

Publication Number Publication Date
WO2000042068A2 WO2000042068A2 (fr) 2000-07-20
WO2000042068A3 true WO2000042068A3 (fr) 2000-12-21
WO2000042068A9 WO2000042068A9 (fr) 2002-04-11

Family

ID=26813196

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/000372 WO2000042068A2 (fr) 1999-01-11 2000-01-07 Nouveaux peptides associes au vih

Country Status (3)

Country Link
EP (1) EP1159297A2 (fr)
AU (1) AU2603100A (fr)
WO (1) WO2000042068A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050420A2 (fr) * 2004-11-01 2006-05-11 Trinity Biosystems, Inc. Immunogenes chimeres comprenant de l'ovalbumine
CA2739905A1 (fr) 2008-10-30 2010-08-26 Dana-Farber Cancer Institute Mimotopes de env vih

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009872A2 (fr) * 1989-12-13 1991-07-11 Univax Biolog Inc Polypeptides selectivement reactifs avec des anticorps contre le virus d'immunodeficience humaine et vaccins comprenant les polypeptides
EP0471407A2 (fr) * 1990-08-13 1992-02-19 Merck & Co. Inc. Réalisations du déterminant neutralisant principal du HIV
WO1994002614A1 (fr) * 1992-07-16 1994-02-03 Medical Research Council PEPTIDES IMITANT LE DETERMINANT ANTIGENIQUE DE gp120 DE HIV
WO1994002626A1 (fr) * 1992-07-20 1994-02-03 Merck & Co., Inc. Conjugues immunologiques d'epitopes de neutralisation principaux selectionnes specifiques du proteosome de la membrane externe et du vih
EP0673948A1 (fr) * 1994-02-23 1995-09-27 BEHRINGWERKE Aktiengesellschaft Peptides dérivés d'un rétrovirus du groupe SIV et leur utilisation
WO1999066046A1 (fr) * 1998-06-12 1999-12-23 Aventis Pasteur Mimotopes du virus hiv
WO1999066957A2 (fr) * 1998-06-20 1999-12-29 United Biomedical Inc. Epitopes de lymphocytes t auxiliaires artificiels tenant lieu d'immunostimulateurs pour constituer des immunogenes peptidiques de synthese

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009872A2 (fr) * 1989-12-13 1991-07-11 Univax Biolog Inc Polypeptides selectivement reactifs avec des anticorps contre le virus d'immunodeficience humaine et vaccins comprenant les polypeptides
EP0471407A2 (fr) * 1990-08-13 1992-02-19 Merck & Co. Inc. Réalisations du déterminant neutralisant principal du HIV
WO1994002614A1 (fr) * 1992-07-16 1994-02-03 Medical Research Council PEPTIDES IMITANT LE DETERMINANT ANTIGENIQUE DE gp120 DE HIV
WO1994002626A1 (fr) * 1992-07-20 1994-02-03 Merck & Co., Inc. Conjugues immunologiques d'epitopes de neutralisation principaux selectionnes specifiques du proteosome de la membrane externe et du vih
EP0673948A1 (fr) * 1994-02-23 1995-09-27 BEHRINGWERKE Aktiengesellschaft Peptides dérivés d'un rétrovirus du groupe SIV et leur utilisation
WO1999066046A1 (fr) * 1998-06-12 1999-12-23 Aventis Pasteur Mimotopes du virus hiv
WO1999066957A2 (fr) * 1998-06-20 1999-12-29 United Biomedical Inc. Epitopes de lymphocytes t auxiliaires artificiels tenant lieu d'immunostimulateurs pour constituer des immunogenes peptidiques de synthese

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
BOOTS LJ ET AL.,: "Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries.", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 13, 10 December 1997 (1997-12-10), pages 1549-1559, XP000907201 *
BUCHBINDER S AND VITTINGHOFF E: "HIV-infected long-term nonprogressors: epidemiology, mechanisms of delayed progression, and clinical and research implications", MICROBES AND INFECTION, vol. 1, November 1999 (1999-11-01), pages 1113 - 1120, XP000911184 *
CONF ADV AIDS VACCINE DEV, 4 May 1997 (1997-05-04), pages p109 *
COTROPIA J ET AL.,: "A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates.", JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, vol. 12, no. 3, 1996, pages 221-232, XP000910872 *
DATABASE AIDSLINE BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; BONNYCASTLE L ET AL.,: "The identification of "HIV-1-mimic" peptides using antibodies from the sera of HIV-1 infected, long-term non-progressors.", XP002139103 *
D'SOUZA M.P. ET AL.,: "Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies fro clinical trials", JOURNAL OF INFECTIOUS DISEASES, vol. 175, 1997, pages 1056-1062, XP000910884 *
FELICI F ET AL: "SELECTION OF ANTIBODY LIGANDS FROM A LARGE LIBRARY OF OLIGOPEPTIDESEXPRESSED ON A MULTIVALENT EXPOSITION VECTOR", JOURNAL OF MOLECULAR BIOLOGY,GB,LONDON, vol. 222, no. 2, 1 January 1991 (1991-01-01), pages 301 - 310, XP000373977, ISSN: 0022-2836 *
HAESEVELDE VANDEN M ET AL: "GENOMIC CLONING AND COMPLETE SEQUENCE ANALYSIS OF A HIGHLY DIVERGENT AFRICAN HUMAN IMMUNODEFICIENCY VIRUS ISOLATE", JOURNAL OF VIROLOGY,US,THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 68, no. 3, 1 March 1994 (1994-03-01), pages 1586 - 1596, XP002034445, ISSN: 0022-538X *
HOGERVORST E ET AL.,: "Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: Low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels", JOURNAL OF INFECTIOUS DISEASES, vol. 171, no. 4, 1995, pages 811-821, XP000910818 *
IDA SETSUKO ET AL: "HIV type 1 V3 variation dynamics in vivo: Long-term persistence of non-syncytium-inducing genotypes and transient presence of syncytium-inducing genotypes during the course of progressive AIDS.", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 13, no. 18, 10 December 1997 (1997-12-10), pages 1597 - 1609, XP000925917, ISSN: 0889-2229 *
MARZO VERONESE DI F ET AL: "STRUCTURAL MIMICRY AND ENHANCED IMMUNOGENICITY OF PEPTIDE EPITOPES DISPLAYED ON FILAMENTOUS BACTERIOPHAGE. THE V3 LOOP OF HIV-1 GP120", JOURNAL OF MOLECULAR BIOLOGY,GB,LONDON, vol. 243, no. 2, 1994, pages 167 - 172, XP000877088, ISSN: 0022-2836 *
MONTEFIORI DAVID C ET AL.,: "Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors.", JOURNAL OF INFECTIOUS DISEASES, vol. 173, no. 1, 1996, pages 60-67, XP000910864 *
PANTALEO G ET AL.,: "Studies in subjects with long-term nonprogressive human immunodeficiency virus infection.", NEW ENGLAND JOURNAL OF MEDICINE, vol. 332, 1995, pages 209-216, XP000910863 *
RUSCONI S ET AL.,: "Patterns of in vitro anti-human immunodeficiency virus type 1 antibody production in long-term nonprogressors.", CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 85, no. 3, 1997, pages 320-323, XP000910865 *
TORAN JL ET AL.,: "Molecular analysis of HIV-1 gp120 antibody response using isotype IgM and IgG phage display libraries from a long-term non-progressor HIV-1-infected individual.", EUR J IMMUNOL, vol. 29 (9), September 1999 (1999-09-01), pages 2666-75, XP000913460 *

Also Published As

Publication number Publication date
AU2603100A (en) 2000-08-01
WO2000042068A9 (fr) 2002-04-11
EP1159297A2 (fr) 2001-12-05
WO2000042068A2 (fr) 2000-07-20

Similar Documents

Publication Publication Date Title
WO2002066012A3 (fr) Liposomes amphoteres et leur utilisation
WO1999010375A3 (fr) Vaccin
WO2002069949A3 (fr) Polytherapie pour la reduction de la toxicite d'agents chimiotherapeutiques
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
WO2002009746A8 (fr) Composition vaccinale
BR9814487A (pt) "vacina"
DE50102597D1 (de) Arzneimittel gegen virale erkrankungen
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
WO2001010456A3 (fr) Peptides bloquant les infections virales et procedes d'utilisation correspondants
AU2001269704A1 (en) Oxazinoquinolones useful for the treatment of viral infections
HUP0200841A2 (en) Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
WO2001040473A3 (fr) Antigenes de pseudomonas aeruginosa
AU2001292125A1 (en) Genetic factors affecting the outcome of viral infections
AU2281601A (en) Treatment of viral infections using levovirinTM
WO2000042068A3 (fr) Nouveaux peptides associes au vih
WO2000015634A3 (fr) Inhibiteurs de la protease du vih
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
AU2002343146A1 (en) Identification of cd8 epitopes from hiv-1 proteins for prevention and therapy of hiv infections
AU2002314331A1 (en) Bacteriophage preparation for the treatment of intracellular bacterial infection
AU2002229850A1 (en) Polypeptide inducing hiv-neutralising antibodies
AU2001287820A1 (en) Use of lipopeptides for immunotherapy of hiv-positive subjects
AU7438301A (en) The use of synthetic, non-hormonal 21-aminosteroids, derivatives, metabolites and precursors thereof in the treatment of viral infections
EP0379295A3 (fr) Anticorps antitryptase et composition pour le traitement du sida utilisant cet anticorps
WO2002069691A3 (fr) Peptides vih immunogenes utilises en tant que reactifs et en tant que vaccins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000904245

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09869003

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000904245

Country of ref document: EP

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/9-9/9, DRAWINGS, REPLACED BY NEW PAGES 1/10-10/10; DUE TO LATE TRANSMITTAL BY THE RECEIVINGOFFICE

WWW Wipo information: withdrawn in national office

Ref document number: 2000904245

Country of ref document: EP